Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

A Engert; P Borchmann; A Pluetschow; B von Tresckow; J Markova; F Hitz; Z Kral; Richard Greil; MS Topp; M Villalobos; JM Zijlstra; M Soekler; H Stein; HT Eich; RP Mueller; M Fuchs; V Diehl

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

A Engert, P Borchmann, A Pluetschow, B von Tresckow, J Markova, F Hitz, Z Kral, Richard Greil, MS Topp, M Villalobos, JM Zijlstra, M Soekler, H Stein, HT Eich, RP Mueller, M Fuchs, V Diehl

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	336-336
Journal	BLOOD
Volume	116
Issue number	21
Publication status	Published - 2010
Event	52nd Annual Meeting of the American-Society-of-Hematology (ASH) - Orlando, FL Duration: 4 Jan 2010 → 7 Jan 2010

Cite this

Engert, A., Borchmann, P., Pluetschow, A., von Tresckow, B., Markova, J., Hitz, F., Kral, Z., Greil, R., Topp, MS., Villalobos, M., Zijlstra, JM., Soekler, M., Stein, H., Eich, HT., Mueller, RP., Fuchs, M., & Diehl, V. (2010). Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. BLOOD , 116(21), 336-336.

Engert, A ; Borchmann, P ; Pluetschow, A et al. / Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. In: BLOOD 2010 ; Vol. 116, No. 21. pp. 336-336.

@article{2bf66b164d6b4dba910fdee6281c8649,

title = "Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial",

author = "A Engert and P Borchmann and A Pluetschow and {von Tresckow}, B and J Markova and F Hitz and Z Kral and Richard Greil and MS Topp and M Villalobos and JM Zijlstra and M Soekler and H Stein and HT Eich and RP Mueller and M Fuchs and V Diehl",

year = "2010",

language = "English",

volume = "116",

pages = "336--336",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

number = "21",

note = "52nd Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 04-01-2010 Through 07-01-2010",

}

Engert, A, Borchmann, P, Pluetschow, A, von Tresckow, B, Markova, J, Hitz, F, Kral, Z, Greil, R, Topp, MS, Villalobos, M, Zijlstra, JM, Soekler, M, Stein, H, Eich, HT, Mueller, RP, Fuchs, M & Diehl, V 2010, 'Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial', BLOOD , vol. 116, no. 21, pp. 336-336.

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. / Engert, A; Borchmann, P; Pluetschow, A et al.
In: BLOOD , Vol. 116, No. 21, 2010, p. 336-336.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

AU - Engert, A

AU - Borchmann, P

AU - Pluetschow, A

AU - von Tresckow, B

AU - Markova, J

AU - Hitz, F

AU - Kral, Z

AU - Greil, Richard

AU - Topp, MS

AU - Villalobos, M

AU - Zijlstra, JM

AU - Soekler, M

AU - Stein, H

AU - Eich, HT

AU - Mueller, RP

AU - Fuchs, M

AU - Diehl, V

PY - 2010

Y1 - 2010

M3 - Abstract (Journal)

SN - 0006-4971

VL - 116

SP - 336

EP - 336

JO - BLOOD

JF - BLOOD

IS - 21

T2 - 52nd Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 4 January 2010 through 7 January 2010

ER -

Engert A, Borchmann P, Pluetschow A, von Tresckow B, Markova J, Hitz F et al. Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. BLOOD . 2010;116(21):336-336.